哪些因素影响退出eculizumab的决定:对被诊断为aHUSUS的患者进行了定性研究
Jan Lecouturier1, Neil Sheerin2
1Population and Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
The patient
|September 12, 2025
概括
患有非典型血溶性尿素综合征 (aHUS) 的患者往往希望停止治疗eculizumab,以获得更正常的生活. 了解患者的经验是指导决定撤销eculizumab和管理复发恐惧的关键.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 血液学 血液学 血液学
- 罕见疾病 罕见疾病
背景情况:
- 非典型的血溶性尿素综合征 (aHUS) 是一种罕见的,危及生命的疾病.
- 目前的治疗包括终身输注eculizumab,但越来越多地考虑停止治疗.
- 患者对eculizumab停药的看法尚不清楚.
研究的目的:
- 探索患者和家长影响eculizumab在aHUS中停用决定的因素.
- 了解正在接受eculizumab戒断的个体的经验和需求.
主要方法:
- 使用深度电话采访进行定性研究.
- 专题分析了来自成人和患有HUS的孩子的父母的数据.
- 进行了跟进采访,与停止使用eculizumab的参与者进行了采访.
主要成果:
- 戒断的原因是对正常生活的渴望和对长期治疗的担忧,尽管HUS的创伤性发作.
- 对复发的担忧是继续治疗的主要驱动因素.
- 两年后,患者报告恢复正常,但仍然担心复发,并意识到需要随访.
结论:
- 患者和家长的经验对于指导有关eculizumab戒断的讨论至关重要.
- 虽然存在替代治疗方法,但核心戒断决策因素仍然存在.
- 需要支持来解决早期的戒断恐惧,试验证据可以提供保证.
相关概念视频
Factors Affecting Protein-Drug Binding: Patient-Related Factors
305
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
305
Factors Affecting Drug Response: Overview
3.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.0K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
257
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
257
Therapeutic Drug Monitoring: Affecting Factors
202
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
202
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
409
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
409
Factors Influencing Drug Absorption: Disease States and Pharmacology
1.3K
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
1.3K

